OGLEMILAST


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	OKFDRAHPFKMAJH-UHFFFAOYSA-N
Smiles	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
InChI	InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)

Mechanism of Action	Action	Reference
Phosphodiesterase 4 inhibitor	INHIBITOR	PubMed


Protein: Phosphodiesterase 4 Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4A Organism : Homo sapiens P27815 ENSG00000065989










Protein: Phosphodiesterase 4 Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4B Organism : Homo sapiens Q07343 ENSG00000184588












Protein: Phosphodiesterase 4 Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4C Organism : Homo sapiens Q08493 ENSG00000105650








Protein: Phosphodiesterase 4 Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4D Organism : Homo sapiens Q08499 ENSG00000113448

Assay Description	Organism	Bioactivity
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-4.26 %
Inhibition of human PDE4D catalytic domain using [3H]-cAMP or [3H]-cGMP incubated for 30 mins by scintillation counting method	Homo sapiens	166.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	10.13 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.29 %	Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.29 %
Antiinflammatory activity in Swiss albino mouse model of LPS-induced sepsis assessed as reduction in TNFalpha production at 10 mg/kg, po administered 30 mins before LPS stimulation and measured after 90 min by ELISA relative to control	Mus musculus	72.5 %
Antiinflammatory activity in Swiss albino mouse model of LPS-induced sepsis assessed as reduction in TNFalpha production at 1 mg/kg, po administered 30 mins before LPS stimulation and measured after 90 min by ELISA relative to control	Mus musculus	53.9 %

CONTENTS